Solid Biosciences Says European Commission Grants Orphan Designation To SGT-212 For Treatment Of Friedreich’s Ataxia
- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia -- SGT-212 is a first-in-class dual route FA
Solid Biosciences got special permission from Europe for a rare disease medicine. This means the company can get help developing the drug faster and cheaper.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.